Clinical Trial Search

Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…

Primary: Fold Increase in ASM Proliferation Following Incubation With Eosinophils. — 2; 2 Fold increase in ASM cell proliferation — p=<0.05

Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74

Primary: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) — 1; 113; 104; 100 Participants — p=<0.001

Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms

Primary: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups — 0.6; -7.5 perecentage of eos per…

Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants

Primary: Number of Participants Who Responded — 7; 4 participants

Primary: Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge — 3.5; 2.4; 0.54; 2.4 Eosinophil percentage

Primary: Mean Change in Dysphagia Score — 15.4; 8.3 score on a scale — p=0.14

Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…

Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants

Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00

Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028

Primary: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) — 10; 19; 14; 16 Participants — p=0.001

Primary: Percent of Participants in Complete Histologic Remission — 100 percentage of participants

Primary: Airway Resistance at 5 Hz (R5) at Baseline (Pre-mepolizumab Initiation) — 0.51; 0.39; 0.43 kPa/L/s

Primary: Number of Participants With Any Adverse Events (AE), Any Serious Adverse Event (SAE) and Drug-related AE During Treatment Phase (TP) and Follow-up Phase (FP) — 18; 15…

Primary: Percentage of Participants Who Attained Remission. — 65.2; 0 percentage of participants

Primary: Mean Percent Change in Eosinophil Count After Glucocorticoid Challenge — -69.6; -13.6 percentage of eosinophil count

Primary: Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During the 32-Week Study Treatment Period — 56; 28 Percentage of participants…

Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage

Primary: Change in Blood Absolute Eosinophil Count From Baseline to Week 12 — 0.8980; 0.4031; 0.3056; 0.2051 ratio to baseline — p=<.0001

Primary: Peak Esophageal Eosinophil Count — 57.3; 71.3 Peak # of eosinophils counted per field

Primary: Change From Baseline in the Peak Esophageal Intraepithelial Eosinophil Count at Week 4 (Mean) — -9.2; -31.6; -7.8 eosinophil count per high power field

Primary: Number of Participants With Nasal Polyp Plasma Cell Transcriptome — 10; 10; 10 Participants

Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1

Primary: Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels — -37.60; -58.27; -56.46; 11.50 percentage change in eosinophils/hpf…

Primary: Esophageal Eosinophilia (Number of Eosinophils in the Esophagus) — 5.3 eosinophils/high power field

Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…